Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats-Reference-Cited by-同舟云学术

Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats

Published:2023 Issue:3 Volume:36 Page:151-158
ISSN:0914-9198
Container-title:Journal of Toxicologic Pathology
language:en
Short-container-title:J Toxicol Pathol

Author:

Nagashima Yoshiyasu¹,Tochinai Ryota¹,Sekizawa Shin-ichi¹,Kato Daiki²,Nakagawa Takayuki²,Tsuru Yoshiharu³,Tatewaki Yasuko⁴,Mutoh Tatsushi⁴,Taki Yasuyuki⁴,Kuwahara Masayoshi¹

Affiliation:

1. Department of Veterinary Pathophysiology and Animal Health, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

2. Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan

3. Primetech Corp. Life Science Laboratory, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan

4. Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryocho, Aobaku, Sendai 980-8575, Japan

Publisher

Japanese Society of Toxicologic Pathology

Subject

Toxicology,Pathology and Forensic Medicine

Link

https://www.jstage.jst.go.jp/article/tox/36/3/36_2022-0143/_pdf

Reference25 articles.

1. 1. Steinmetz MO, and Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 28: 776–792. 2018.

2. 2. Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, and Cichoń T. Vascular disrupting agents in cancer therapy. Eur J Pharmacol. 891: 173692. 2021.

3. 3. Abma E, De Spiegelaere W, Vanderperren K, Stock E, Van Brantegem L, Cornelis I, Daminet S, Ni Y, Vynck M, Verstraete G, Smets P, and de Rooster H. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. Vet Comp Oncol. 16: 467–477. 2018.

4. 4. Grisham R, Ky B, Tewari KS, Chaplin DJ, and Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 5: 1. 2018.

5. 5. Subbiah IM, Lenihan DJ, and Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist. 16: 1120–1130. 2011.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti‐tumor and cardiotoxic effects of microtubule polymerization inhibitors: The mechanisms and management strategies;Journal of Applied Toxicology;2023-07-26